Mai Capital Management Neurocrine Biosciences Inc Transaction History

Mai Capital Management

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	BUY	$72.45 - $94.81 $53,975 - $70,633	745 Added 13.15%	6,412 $601,000
Q4 2021 Feb 11, 2022	BUY	$79.65 - $106.22 $28,275 - $37,708	355 Added 6.68%	5,667 $483,000
Q3 2021 Nov 12, 2021	BUY	$86.18 - $99.03 $14,736 - $16,934	171 Added 3.33%	5,312 $509,000
Q2 2021 Jul 19, 2021	SELL	$89.43 - $102.27 $178 - $204	-2 Reduced 0.04%	5,141 $500,000
Q1 2021 May 10, 2021	BUY	$87.57 - $119.4 $66,728 - $90,982	762 Added 17.39%	5,143 $500,000
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $93,428 - $116,454	-1,075 Reduced 19.7%	4,381 $420,000
Q3 2020 Oct 26, 2020	BUY	$96.16 - $135.15 $524,648 - $737,378	5,456 New	5,456 $525,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

Stay updated on Mai Capital Management with notifications on news.